Chronic myelogenous leukemia. Curable with early diagnosis and treatment.
CML is diagnosed most commonly in middle-aged patients following referral from primary care physicians. The majority of patients live at least 5 years when the disease is diagnosed and treated in the chronic phase. Survival is clearly prolonged by therapy, including interferon alfa-2b (used alone or in combination with other agents) and allogeneic bone marrow transplantation. With ongoing advances in allogeneic transplantation allowing matched related and unrelated donor transplants in older individuals with manageable complications, the need for timely identification of CML patients who are suitable candidates for this potentially curative intervention is critical.
Hill
J M
JM
Uniformed Services University of the Health Sciences, Division of Hematology/Oncology, National Naval Medical Center, Bethesda, USA.
Meehan
K R
KR
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins